Genetically modified mesenchymal stem cells for use in cardiovascular prosthetics
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorCynthia St. Hilaire
Life of this patent
Estimating the term…
Abstract
A cardiovascular graft is provided, such as a prosthetic heart valve or blood vessel, that comprises mesenchymal stem cells (MSCs) and/or progeny thereof, modified to knock down or knockout expression of the telomerases reverse transcriptase gene (TERT), or otherwise reduce activity of TERT. Also provided are a method of making the cardiovascular graft, and a method of implanting the cardiovascular graft.
Claims22
A cardiovascular graft, comprising mesenchymal stem cells (MSCs), modified to reduce or eliminate expression or activity of telomerase reverse transcriptase (TERT) or cells differentiated from the modified MSCs modified to reduce or eliminate expression or activity of TERT, wherein
- the MSCs are treated with a TERT-interfering RNA to reduce or eliminate expression of TERT in the MSCs, and/or
- the MSCs are genetically modified to knock out or to knock down expression of TERT.
A method of preparing a cardiovascular
- graft, comprising seeding a bioerodible cell growth scaffold with mesenchymal stem cells (MSCs) that are modified to reduce or eliminate expression or activity of telomerase reverse transcriptase (TERT), wherein
- the MSCs are treated with a TERT-interfering RNA to reduce or eliminate expression of TERT in the MSCs, and/or
- the MSCs are genetically modified to knock out or to knock down expression of TERT.
A method of treating a cardiovascular defect or injury in a patient, comprising implanting or depositing at a site of a defect or injury in a patient a cardiovascular graft comprising mesenchymal stem cells (MSCs), modified to reduce or eliminate expression or activity of telomerase reverse transcriptase (TERT) or cells differentiated from the modified MSCs modified to reduce or eliminate expression or activity of TERT, wherein
- the MSCs are treated with a TERT-interfering RNA to reduce or eliminate expression of TERT in the MSCs, and/or
- the MSCs are genetically modified to knock out or to knock down expression of TERT.
Dependencies are inferred from the claim text.